First Report of BAP1 ‐Associated Polyposis
American Journal of Medical Genetics Part A · 2025
DOI: 10.1002/ajmg.a.64176 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Angela L Jacobson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Adenomatous Polyposis Coli, Genetic Predisposition to Disease. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH SPORE, National Cancer Institute.
Abstract (Originalsprache)
BAP1 Tumor Predisposition Syndrome ( BAP1 ‐TPDS) is caused by germline pathogenic variants in the BAP1 gene and has been associated with uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and other benign cutaneous lesions. Adenomatous colon polyposis has not previously been reported as part of BAP1 ‐TPDS. We report two patients with unexplained adenomatous oligopolyposis and germline BAP1 pathogenic variants. To determine if BAP1 had a role in polypogenesis, we performed somatic mutational analysis on multiple polyps from both patients ( n = 8 total polyps tested). In every polyp tested, we found evidence of second BAP1 allele inactivation, including second somatic BAP1 mutations. Further, we did not detect any mutations in the commonly identified adenomatous polyposis pathway drivers, APC , CTNNB1 , or other WNT/β‐catenin. We did not detect somatic BAP1 mutations in any adenomatous polyps from patients without germline BAP1 pathogenic variants ( n = 151 patients), highlighting the specificity of somatic BAP1 second hit mutations in BAP1 germline carrier polyps. Our findings strongly support that the polyps in these patients were caused by BAP1 , and that adenomatous oligopolyposis is a part of the BAP1 ‐TPDS tumor spectrum. Further work is needed to characterize the penetrance of this new BAP1 ‐associated phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
- Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
- Division of Gastroenterology, Hepatology & Nutrition, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
- Department of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University, Columbus, Ohio, USA.
- Brotman Baty Institute for Precision Medicine, Seattle, Washington, USA.
ORCID-Profile: Angela L Jacobson, Maegan E Roberts, Lindsey Byrne, Mohamed H Abdel-Rahman
Förderung
- NCI NIH HHS
- NIH SPORE
- National Cancer Institute
Zitieren
APA
Jacobson, A. L., Roberts, M. E., Byrne, L., Wolfe, J., Stanich, P. P., Abdel-Rahman, M. H., Pritchard, C. C., & Konnick, E. Q. (2025). First Report of BAP1 ‐Associated Polyposis. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.64176
Vancouver
Jacobson AL, Roberts ME, Byrne L, Wolfe J, Stanich PP, Abdel-Rahman MH, et al. First Report of BAP1 ‐Associated Polyposis. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.64176
BibTeX
@article{Jacobson2025,
author = {Jacobson, Angela L and Roberts, Maegan E and Byrne, Lindsey and Wolfe, Jenna and Stanich, Peter P and Abdel-Rahman, Mohamed H and Pritchard, Colin C and Konnick, Eric Q},
title = {First Report of BAP1 ‐Associated Polyposis},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
doi = {10.1002/ajmg.a.64176}
}
EUVIMED